Clinical Scorecard: Comparison of FibroScan-AST Score and Liver Stiffness in Predicting Liver Complications Following HCV Treatment Success

At a Glance

Key Highlights

• Liver stiffness (LS) independently predicts liver complications including decompensation and hepatocellular carcinoma (HCC) after SVR.
• FAST score ≥0.35 is independently associated with increased risk of liver complications but does not outperform LS alone in predictive capacity.
• 44% of patients had fatty liver disease (CAP ≥248 dB/m) at SVR, highlighting the role of steatotic liver disease in post-SVR outcomes.

Guideline-Based Recommendations

Diagnosis

• Use vibration-controlled transient elastography (VCTE) to measure liver stiffness (LS) and controlled attenuation parameter (CAP) at SVR.
• Calculate FAST score incorporating LS, AST, and CAP to assess risk of liver complications.
• Diagnose hepatic decompensations clinically and HCC according to American Association for the Study of Liver Diseases criteria.

Management

• Continue surveillance for liver complications post-SVR, especially in patients with LS ≥9.5 kPa pretreatment.
• Perform biannual HCC screening with alpha-fetoprotein and liver ultrasound in patients with cirrhosis.
• Conduct gastroesophageal varices surveillance with endoscopy in patients with LS ≥21 kPa.

Monitoring & Follow-up

• Clinical and analytical evaluation every 6 months post-SVR.
• Regular VCTE assessments to monitor liver stiffness and steatosis status.
• Monitor for liver-related events including hepatic decompensation and HCC.

Risks

• Patients with higher LS and FAST scores have increased risk of liver complications despite SVR.
• Presence of fatty liver disease may contribute to fibrogenesis and hepatocarcinogenesis post-SVR.
• Limited positive predictive value of LS alone necessitates comprehensive risk assessment.

Patient & Prescribing Data

Patients with chronic HCV infection (with or without HIV coinfection) achieving SVR after DAA therapy with advanced fibrosis (LS ≥9.5 kPa).

DAA-based regimens effectively achieve SVR; however, liver stiffness and FAST score remain important for risk stratification of liver complications post-treatment.

Clinical Best Practices

• Incorporate LS measurement via VCTE at SVR to stratify risk for liver complications.
• Use FAST score as an adjunct to identify patients with steatohepatitis and higher risk but rely primarily on LS for prediction.
• Maintain regular surveillance protocols including imaging and laboratory tests for early detection of liver events.
• Manage patients with cirrhosis according to established protocols including HCC and varices screening.

References

• American Association for the Study of Liver Diseases HCC Diagnosis Criteria
• GEHEP-011 Cohort Clinical Trial Registration